doi: 10.1161/01.CIR.0000143098.98869.F8
(Circulation. 2004;110:2066-2071.)
© 2004 American Heart Association, Inc.
Basic Science for Clinicians |
Genetic Basis of Atherosclerosis: Part II
Clinical Implications
From the Division of Cardiology (A.J.L., A.M.F., G.C.F.), the Department of Microbiology, Immunology and Molecular Genetics (A.J.L.), and the Department of Human Genetics (A.J.L.), David Geffen School of Medicine at University of California, Los Angeles.
Correspondence to Aldons J. Lusis, Department of Medicine/Division of Cardiology, 47-123 CHS, Los Angeles, CA 90095-1679. E-mail jlusis@mednet.ucla.edu
Key Words: atherosclerosis • diagnosis • genetics • lipoproteins • prevention
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
Knowledge of genetic factors in the etiology of coronary heart disease has not so far been adequately utilized in attempts to combat premature CHD. The time has now come to utilize genetic information in a setting of family-oriented preventive medicine. This approach would greatly improve the efficiency of preventive efforts, utilizing predictive genetic testing and targeting counseling on those who need it most.1
The optimistic predictions of the impact of genetics on the diagnosis and prevention of coronary heart disease (CHD) have not been realized, and whether DNA testing will be incorporated into clinical cardiology practice in the next decades is unclear. Most of the genetic variations identified thus far either are rare or influence traditional risk factors such as low HDL, elevated LDL, high blood pressure, and diabetes. Several recent advances, however, make a case for renewed optimism (see Part I of this review). Studies in humans and mice have begun to reveal highly penetrant genetic factors that contribute to CHD susceptibility independent of traditional risk factors. As technical advances bring down genotyping costs, we may pass a threshold for the cost–benefit ratio in the near future. One important application in diagnosis is likely to involve the identification of different forms of CHD to allow individualized treatment (pharmacogenetics). The application of multilocus genotyping to assess risk or to screen populations for individuals who are highly susceptible to CHD also is a possibility. Perhaps most important, genetic studies are leading to many insights into disease mechanisms, and these studies, along
This article has been cited by other articles:
 |
|
 |
|
  P. W.F. Wilson Progressing From Risk Factors to Omics Circ Cardiovasc Genet, December 1, 2008; 1(2): 141 - 146. [Full Text] [PDF]
|
|
|
|
|
|
D. I. Chasman, G. Pare, R. Y.L. Zee, A. N. Parker, N. R. Cook, J. E. Buring, D. J. Kwiatkowski, L. M. Rose, J. D. Smith, P. T. Williams, et al. Genetic loci associated with plasma concentration of LDL-C, HDL-C, triglycerides, ApoA1, and ApoB among 6382 Caucasian women in genome-wide analysis with replication. Circ Cardiovasc Genet, October 1, 2008; 1(1): 21 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ciszewski, Z. T. Bilinska, L. B. Brydak, C. Kepka, M. Kruk, M. Romanowska, E. Ksiezycka, J. Przyluski, W. Piotrowski, R. Maczynska, et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study Eur. Heart J., June 1, 2008; 29(11): 1350 - 1358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. A. Iakoubova, C. H. Tong, C. M. Rowland, T. G. Kirchgessner, B. A. Young, A. R. Arellano, D. Shiffman, M. S. Sabatine, H. Campos, C. J. Packard, et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J. Am. Coll. Cardiol., January 29, 2008; 51(4): 435 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Arnett and for the Writing Group Summary of the American Heart Association's Scientific Statement on the Relevance of Genetics and Genomics for Prevention and Treatment of Cardiovascular Disease Arterioscler Thromb Vasc Biol, August 1, 2007; 27(8): 1682 - 1686. [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Arnett, A. E. Baird, R. A. Barkley, C. T. Basson, E. Boerwinkle, S. K. Ganesh, D. M. Herrington, Y. Hong, C. Jaquish, D. A. McDermott, et al. Relevance of Genetics and Genomics for Prevention and Treatment of Cardiovascular Disease: A Scientific Statement From the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group Circulation, June 5, 2007; 115(22): 2878 - 2901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Hegele and R. L. Pollex Apolipoprotein A-V Genetic Variation and Plasma Lipoprotein Response to Fibrates Arterioscler Thromb Vasc Biol, June 1, 2007; 27(6): 1224 - 1227. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yamasaki, N. Katakami, K. Sakamoto, H. Kaneto, M. Matsuhisa, H. Sato, M. Hori, M. Haneda, A. Kashiwagi, Y. Tanaka, et al. Combination of multiple genetic risk factors is synergistically associated with carotid atherosclerosis in Japanese subjects with type 2 diabetes. Diabetes Care, November 1, 2006; 29(11): 2445 - 2451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ohashi, H. Mu, X. Wang, Q. Yao, and C. Chen Reverse cholesterol transport and cholesterol efflux in atherosclerosis QJM, December 1, 2005; 98(12): 845 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Loew, M. M. Hoffmann, W. Koenig, H. Brenner, and D. Rothenbacher Genotype and Plasma Concentration of Cystatin C in Patients With Coronary Heart Disease and Risk for Secondary Cardiovascular Events Arterioscler Thromb Vasc Biol, July 1, 2005; 25(7): 1470 - 1474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Futterman and L. Lemberg Apo A-I Milano Am. J. Crit. Care., May 1, 2005; 14(3): 244 - 247. [Full Text] [PDF]
|
|